Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun:100:137-139.
doi: 10.1016/j.ejim.2022.03.001. Epub 2022 Mar 14.

Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

Noah Shopen  1 , Michal Dekel  2 , Michal Mizrahi  3 , Efrat Zandberg  4 , Daniel Talmud  5 , Neta Cohen  6 ; Tel Aviv Sourasky Medical Center Emergency Department study group
Affiliations

Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

Noah Shopen et al. Eur J Intern Med. 2022 Jun.
No abstract available

Keywords: BNT162b2 vaccine; Casirivimab/Imdevimab therapy; High-risk patients; SARS-CoV-2 delta variant; Severe outcome.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests to disclose.

References

    1. Docherty A.B., et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterization protocol: prospective observational cohort study. BMJ. 2020;369:m1985. - PMC - PubMed
    1. Weinreich D.M., Sivapalasingam S., Norton T., et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238–251. - PMC - PubMed
    1. He X., He C., Hong W., Zhang K., Wei X. The challenges of COVID-19 Delta variant: Prevention and vaccine development. MedComm. 2020;2(4):846–854. doi: 10.1002/mco2.95. [published online ahead of print, 2021 Oct 19] 2021. - DOI - PMC - PubMed
    1. Bierle D.M., Ganesh R., Tulledge-Scheitel S., et al. Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities. J Infect Dis. 2021:jiab570. doi: 10.1093/infdis/jiab570. [published online ahead of print, 2021 Nov 16] - DOI - PMC - PubMed
    1. Recovery Collaborative Group. Horby P.W., Mafham M., Peto L., et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021 06.15. - PMC - PubMed

Supplementary concepts